Prescient Therapeutics Limited provided an update on its clinical trials following removal of all clinical holds on its PTX-200 clinical trials. All PTX-200 trials are now off clinical hold and are either currently recruiting or in the process of obtaining requisite institutional-level approvals to recommence recruitment. Prescient is currently undertaking another manufacturing run of PTX-200 to meet increased clinical needs. An important near-term milestone is the release of the final Phase 1b results of PTX-200 with paclitaxel in locally advanced and metastatic HER2-negative breast cancer. Final results from the Phase 1b trial are expected First Quarter 2018. The clinical hold was lifted without amendment to the dosing schedule, meaning that this trial can effectively recommence from where it stopped. The trial is currently in Phase 2, with 5 patients qualifying for Phase 2 data analysis. Based on final Phase 1b results, Prescient will take the opportunity to modify the protocol with a view to strengthening Phase 2 analysis; in particular, stratifying patients based on their hormone receptor status to observe responses in these different breast cancer sub-types. Recruitment for Phase 2 will then recommence under this revised design, expected around the middle of 2018.